Physician profile
Ryan William Stidham
NPI 1467517797
$83,415.24
in general payments reported to CMS, 2019-2025
10 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $3,821 · 2021: $15K · 2022: $9,171 · 2023: $16K · 2024: $9,240 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,230.00 |
| Food and Beverage | $543.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,483.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24,168.56 | 2019-2025 | Entyvio |
| Janssen Research & Development, LLC | $8,676.25 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $6,927.77 | 2022-2023 | |
| Eli Lilly and Company | $6,600.00 | 2021 | |
| Pfizer INC. | $3,780.00 | 2023 | |
| Gilead Sciences, INC. | $3,725.00 | 2021 | |
| Boehringer Ingelheim International Gmbh | $2,034.00 | 2022 | |
| Janssen Biotech, INC. | $20.56 | 2024 | Stelara |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Stidham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.